Mr Stein’s resignation is not due to any disagreement with the company on any matter related to its operations, policies, and practices, the company said.
David Hirsch, the company’s CFO and COO, will assume additional responsibilities as acting CEO and Robert Zahradnik, the company’s vice president of business development, will assume the role of acting COO formerly served by Mr Hirsch.
Richard Welch, chairman of the board of Oragenics, said: “We look forward to continuing to work with Stan in certain select matters relating to strategic alternatives, business development and capital strategies. Also, the board is very confident that David Hirsch has the requisite skill sets to effectively lead the company at this time and continue to move things forward in a very exciting year for the company.”